Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Equity Income (2022 - 2023)

Zentalis Pharmaceuticals has reported Equity Income over the past 2 years, most recently at -$13.7 million for Q2 2023.

  • Quarterly results put Equity Income at -$13.7 million for Q2 2023, down 156.73% from a year ago — trailing twelve months through Mar 2024 was -$13.7 million (up 18.63% YoY), and the annual figure for FY2023 was -$16.0 million, up 1.65%.
  • Equity Income for Q2 2023 was -$13.7 million at Zentalis Pharmaceuticals, down from -$2.3 million in the prior quarter.
  • Over the last five years, Equity Income for ZNTL hit a ceiling of -$1.8 million in Q1 2022 and a floor of -$13.7 million in Q2 2023.